Atlas Trials

Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)

Clinical trial NCT06418087 · RECRUITING

Trial details

NCT number
NCT06418087
Sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Pulmonary Large-cell Neuroendocrine Carcinoma
Start date
2022-05-27
Primary completion
2026-12-31
Enrollment
49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.